Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 2a 1Lethal Congenital Contracture Syndrome 2 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 242Lenalidomide 147daratumumab 125Bortezomib 102pomalidomide 88Calcium Dobesilate 76carfilzomib 75Cyclophosphamide 71Specimen Handling 42isatuximab 41Biopsy 40belantamab mafodotin 37fludarabine 36Magnetic Resonance Spectroscopy 35talquetamab 29Melphalan 28dexamethasone acetate 27dexamethasone 21-phosphate 27auricularum 26iberdomide 25ixazomib 22fludarabine phosphate 22selinexor 21elotuzumab 21Whole-Body Irradiation 14X-Rays 13tocilizumab 12venetoclax 11Mycophenolic Acid 10trametinib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Antibodies, Bispecific × 1 year × Clear all
NCT07051850 2025-07-15

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

Seoul St. Mary's Hospital

Recruiting
174 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡